Could a virtual reality headset offer a cheaper, easier, and more comfortable method of testing a person's vision, particularly among patients with a degenerative eye condition called geographic atrophy? This is a question that ophthalmologists like Dr. Jesse Smith, an associate professor at the University of Colorado Anschutz Department of Ophthalmology, are exploring. And the preliminary findings are quite promising.
In a small study of 24 patients with geographic atrophy at the Sue Anschutz-Rodgers Eye Center, Dr. Smith and his team compared a standard vision testing method called microperimetry with a VR-based test. The results were striking: the VR test delivered similar results to the microperimetry test, suggesting that VR headsets could be a viable alternative for assessing patients' vision, especially when evaluating the effectiveness of new drugs for geographic atrophy. However, further studies are needed to confirm these findings.
Dr. Smith explains that microperimetry is a valuable tool for assessing functional vision benefits of drugs, but it's not the most practical test. The study aimed to find a better alternative. Geographic atrophy, a form of dry age-related macular degeneration, affects older adults, causing a loss of central vision due to missing light-sensing cells in the retina. This condition is becoming more prevalent as people live longer, and it's more common in individuals with Northern or Eastern European ancestry.
The importance of functional tests cannot be overstated. Two drugs, Syfovre and Izervay, were approved by the FDA in 2023 for treating geographic atrophy, but the European Medicines Agency did not approve Syfovre, citing a lack of clinically meaningful benefits. The criticism highlights the need for functional benefits in drug approval, as patients want to see improvements in their quality of life.
Microperimetry, a visual field test, assesses the central vision, making it crucial for evaluating the function of the retina's reading or driving area. It involves a patient looking into a device that measures light sensitivity in the central retina, revealing potential blind spots. However, microperimetry has its drawbacks, including bulkiness, cost, and time-consuming nature.
Dr. Smith decided to explore VR headsets as an alternative, partnering with Genentech. The VR-based test involves a patient wearing a headset and interacting with a virtual assistant to navigate the test. Patients press a button when they see a light in their visual field, and the headset tracks their gaze. The study found a tight statistical correlation between the VR test and microperimetry, indicating similar information retrieval.
The patients' feedback was positive, favoring the VR headset for its comfort and ease of use. The VR test is also more affordable, quicker, and space-efficient compared to microperimetry. However, microperimetry provides a physical image of the retina, which the VR test does not. Dr. Smith believes that VR-based assessments could be a reasonable clinical trial endpoint for drug approval, as they offer a faster, easier, and more comfortable alternative.
The study's findings were presented at The Retina Society's Annual Scientific Meeting in Chicago, and Dr. Smith is working on publishing the research. With the need for more treatments for geographic atrophy, VR-based tests could be a game-changer, offering a practical and effective method for assessing patients' vision.
